Other News To Note
Monday, April 11, 2011
Polaris Group, of San Diego, said preclinical data for ADI-PEG-20, pegylated arginine deiminase, showed that it may effectively treat acute myeloid leukemia, glioblastoma multiforme and bladder cancer. In those cancers, hypermethylation of a promoter gene for arginosuccinate synthetase leads to a deficiency of the enzyme, which causes tumors to be reliant on externally supplied arginine. ADI-PEG-20 degrades arginine, depriving the tumor of that nutrient. Polaris is preparing to begin pivotal Phase III trials of the drug in hepatocellular carcinoma.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.